• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.25
  • VXN 17.82
  • VXO 15.25
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. Its lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. The company is also developing CEL-1000, which is derived from a pre-clinical technology called ?Ligand Epitope Antigen Presentation System? to stimulate the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer; and CEL-2000 for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.

NO
     
CVM (CEL-SCI Corp)
Last Trade 7.85 Date 10/18/2019
Change % -5.54 % Price Change -0.46
Open 8.31 52 Week High 9.93
High 8.32 52 Week Low 2.3668
Low 7.817 Type stock
Volume 542070 Average Volume 686792
Prev Close 8.31 Stock Exchange A
Bid 7.72 Ask 8.48
Bid Size 0 Ask Size 20
1st Yr Estimated EPS Growth 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 0.0329 Book Value Yield 0.0042
Buy Back Yield CAPE Ratio
Cash Return -0.0614 Cash Flow per Share -0.5816
Cash Flow Yield -0.0741 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.1631 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income
EV / Revenue EV / Total Asset 9.732
Expected Dividend Growth Rate Free Cash Flow per Share -0.5936
Free Caash Flow Ratio Free Cash Flow Yield -0.0756
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 238.350034 PB Ratio 10 Year Growth 0.212367
PB Ratio 3 Year Growth 9009.200373 Cash Ratio 3 Year Average 1955.2995
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 0.878076
Price to Cash Ratio 28.804148 Price / EBITDA
Price to Sales Ratio Price to Sales Ratio 10 Year Growth
Price to Sales Ratio 3 Year Avg Price to Sales Ratio 5 Year Avg
Sale per Share 0.0 Sales Yield 0.0
Sustainable Growth Rate Tangible Book Value per Share 0.0251
Tangible Book Value per Share 3 year Avg -0.1455 Tangible Book Value per Share 5 year Avg 0.2536
Total Asset per Share 0.8184 Total Yield
Working Capital per Share 0.1829 Working Capital per Share 3 Year Avg -0.0578
Working Capital per Share 5 Year Avg 0.5059 Beta 4.762618